€28.40
0.00%
Xetra, Tue, Jun 10 2025
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

Key metrics

Basic
Market capitalization
€1.4b
Enterprise Value
€2.0b
Net debt
€608.9m
Cash
€59.8m
Shares outstanding
39.6m
Valuation (TTM | estimate)
P/E
- | -
P/S
2.21 | 1.95
EV/Sales
3.16 | 2.79
EV/FCF
139.56
P/B
-
Dividends
DPS
€0.04
Yield 1Y | 5Y
0.14% | 0.11%
Growth 1Y | 5Y
100.00% | 0.00%
Payout 1Y | 3Y
5.97% | 2.61%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€635.2m | €719.1m
EBITDA
- | €149.5m
EBIT
€11.9m
Net Income
€-24.5m | €60.0m
Free Cash Flow
€14.4m
Growth (TTM | estimate)
Revenue
-15.85% | -0.97%
EBITDA
- | 55.71%
EBIT
-93.30%
Net Income
-116.43% | 127.08%
Free Cash Flow
-37.39%
Margin (TTM | estimate)
Gross
23.19%
EBITDA
- | 20.79%
EBIT
1.87%
Net
-3.86% | 8.34%
Free Cash Flow
2.27%
Financial Health
Equity Ratio
37.01%
Return on Equity
4.97%
ROCE
0.95%
ROIC
0.93%
Debt/Equity
1.31
More
EPS
€-0.62
FCF per Share
€0.36
Short interest
-
Employees
2.50k
Rev per Employee
€290.00k
Show more

Is BIOTEST AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,951 stocks worldwide.

BIOTEST AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a BIOTEST AG forecast:

3x Hold
43%
4x Sell
57%

Analyst Opinions

7 Analysts have issued a BIOTEST AG forecast:

Hold
43%
Sell
57%

Financial data from BIOTEST AG

Assets
Mar '25
789 789
Cash 60 60
Claims 197 197
Inventories 524 524
Other current assets Other current assets Current assets 8.30 8.30
628 628
Property, plant and equipment 567 567
Financial assets 16 16
Intangible Assets 16 16
Other fixed assets Other assets Fixed assets 29 29
Total Assets 1,417 1,417
Liabilities
Mar '25
Equity 510 510
907 907
Current liabilities 160 160
Non-current liabilities 747 747
Total Capital 1,417 1,417

In millions EUR.

Don't miss a Thing! We will send you all news about BIOTEST AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,495
Founded 1946
Website www.biotest.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today